Axsome Therapeutics (AXSM) Cash from Investing Activities (2015 - 2026)
Axsome Therapeutics (AXSM) reported Cash from Investing Activities of -$121000.0 for Q1 2026, up 64.2% on a YoY basis from -$73690.1 in Q1 2025, and down 70.42% sequentially from -$71000.0 in Q4 2025.
Axsome Therapeutics (AXSM) Cash from Investing Activities (2015 - 2026) Analysis & Trends
Axsome Therapeutics (AXSM) has 12 years of Cash from Investing Activities data on file, last reported at -$121000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 64.2% year-over-year to -$121000.0; the trailing twelve-month figure through Mar 2026 stood at -$263000.0 (up 48.43% YoY), and the FY2025 full-year result was -$480000.0, down 77.78% from the prior year.
- Cash from Investing Activities eased to -$121000.0 in Q1 2026, from -$71000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$7000.0 in Q4 2023 to a low of -$53.2 million in Q2 2022.
- A 5-year average of -$3.2 million and a median of -$90000.0 in 2024 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities sank 281941.64% in 2022 and surged 99.75% in 2023, its largest moves.
- Tracing AXSM's Cash from Investing Activities over 5 years: stood at -$181000.0 in 2022, then surged by 96.13% to -$7000.0 in 2023, then plunged by 328.57% to -$30000.0 in 2024, then plunged by 136.67% to -$71000.0 in 2025, then tumbled by 70.42% to -$121000.0 in 2026.
- Business Quant data shows AXSM's Cash from Investing Activities at -$121000.0 in Q1 2026, -$71000.0 in Q4 2025, and -$58000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Axsome Therapeutics | 12.28 Bn | 11.98 Bn | 176.48 Mn | -121,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -121,000.00 |
| Mar 31, 2026 | -121,000.00 |
| Dec 31, 2025 | -71,000.00 |
| Dec 31, 2025 | -71,000.00 |
| Sep 30, 2025 | -58,000.00 |
| Sep 30, 2025 | -58,000.00 |
| Jun 30, 2025 | -13,000.00 |
| Jun 30, 2025 | -13,000.00 |
| Mar 31, 2025 | -338,000.00 |
| Mar 31, 2025 | -338,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Dec 31, 2024 | -30,000.00 |
| Sep 30, 2024 | -90,000.00 |
| Sep 30, 2024 | -90,000.00 |
| Jun 30, 2024 | -52,000.00 |
| Jun 30, 2024 | -52,000.00 |
| Mar 31, 2024 | -98,000.00 |
| Mar 31, 2024 | -98,000.00 |
| Dec 31, 2023 | -7,000.00 |
| Dec 31, 2023 | -7,000.00 |